Investors who bought or otherwise acquired Ardelyx common stock between January 13, 2025 and August 6, 2026 may be covered by a proposed class action alleging Ardelyx misled investors about the growth prospects of its drugs IBSRELA and XPHOZAH while insurer restrictions were slowing new patients. No class has been certified and there is nothing to file yet.
Allegations Only · No Settlement Yet
This article describes a class action complaint. The statements below are unproven allegations. Ardelyx, Inc. and its current and former executives have not been found liable, there is no certified class, and nothing to claim at this time. This page is informational and is not legal advice.
What Is This About?
An Ardelyx shareholder filed a proposed securities class action against the company and four of its current and former executives on September 17, 2026 in the U.S. District Court for the District of Massachusetts, in Boston. The case is Broadwater v. Ardelyx, Inc., No. 1:26-cv-14270. It is brought on behalf of investors who bought or otherwise acquired Ardelyx common stock between January 13, 2025 and August 6, 2026.Ardelyx, based in Waltham, Massachusetts, sells two drugs: IBSRELA, for irritable bowel syndrome with constipation, and XPHOZAH, for reducing serum phosphorus in adults with chronic kidney disease on dialysis. Its stock trades on the Nasdaq under the ticker ARDX. The complaint alleges that the company and its executives expressed confidence in both drugs’ growth and in Ardelyx’s revenue guidance while insurers were adding restrictions that slowed new patients. It points to August 6, 2026, when Ardelyx cut its 2026 IBSRELA guidance and withdrew its long-term XPHOZAH target, as the day the alleged truth came out.
The case is at the complaint stage. No lead plaintiff has been appointed, no class has been certified, and there is no settlement, fund or claim form.
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
The IBSRELA and XPHOZAH Growth Statements
The class period opens on January 13, 2025, when Ardelyx reported about $319 million in 2024 U.S. net product sales. According to the complaint, the company said it expected XPHOZAH to reach $750 million in peak annual U.S. sales and reaffirmed that IBSRELA could exceed $1 billion in annual sales at peak. The complaint cites similar statements through 2025 at investor conferences and on quarterly earnings calls.On February 19, 2026, Ardelyx reported that IBSRELA revenue grew 73% in 2025 and issued 2026 guidance of $410 million to $430 million for IBSRELA and $110 million to $120 million for XPHOZAH. The complaint quotes chief executive Michael Raab saying on the earnings call that “our patient-first strategy is working,” that more patients had access to XPHOZAH than ever, and that IBSRELA was “on track to deliver $1 billion in revenue in 2029.” On April 30, 2026, Ardelyx reported first-quarter product revenue of $93.4 million, up 38%, and reaffirmed its 2026 guidance for both drugs.
What the Complaint Alleges Was Misleading
The complaint alleges that the statements made from January 2025 through April 2026 were false or misleading because they gave the impression that Ardelyx had reliable information about its growth prospects and its ability to meet its revenue guidance, based on programs it said were addressing insurer and patient-access barriers, such as its IBSRELA Pharmacy Network, field reimbursement managers, sales-force changes and the ArdelyxAssist program. In truth, the complaint alleges, the company was seeing increasingly restrictive payer requirements, including more stringent prior authorization and step edit requirements, that were slowing new IBSRELA patient starts and delaying prescriptions, and other market-access problems that were undermining XPHOZAH’s long-term growth prospects.The August 6, 2026 Guidance Cut and Stock Drop
On August 6, 2026, after the market closed, Ardelyx reported second-quarter 2026 results. According to the complaint, the company said IBSRELA revenue was below expectations because of “significantly increased utilization management processes from payors,” cut its 2026 IBSRELA revenue guidance to $350 million to $370 million, and reiterated its 2026 XPHOZAH guidance of $110 million to $120 million. Ardelyx kept its long-term goal of $1 billion in IBSRELA revenue while saying it was evaluating the timing, and withdrew its long-term XPHOZAH guidance, which the complaint puts at $650 million, as it assessed evolving market dynamics.The complaint quotes chief commercial officer Eric Foster saying on the earnings call that the company had “experienced significant payer hurdles that had a direct impact on access to IBSRELA,” and that new patient starts had slowed even as refills and total prescriptions grew. According to the complaint, Ardelyx stock fell from a closing price of $4.87 on August 6, 2026 to $4.00 on August 7, a one-day decline of about 18%.
Who Is Being Sued and Under Which Laws
The defendants are Ardelyx, Inc.; Michael Raab, its president and chief executive officer; Justin Renz, its chief financial officer until November 4, 2025; Susan Hohenleitner, who succeeded Renz as chief financial officer on November 4, 2025; and Eric Foster, its chief commercial officer.The complaint asserts two claims:
- Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, against all defendants.
- Section 20(a) of the Exchange Act, a control-person claim against Raab, Renz, Hohenleitner and Foster.
These claims require the plaintiff to show, among other things, that the defendants made false or misleading statements with intent to mislead or with severe recklessness, and that the statements caused investors’ losses. The complaint seeks class certification, damages, interest, and attorneys’ fees and costs, and it demands a jury trial. None of the allegations has been tested in court.
Who Is in the Proposed Class?
The proposed class is everyone who bought or otherwise acquired Ardelyx common stock between January 13, 2025 and August 6, 2026, inclusive, and was damaged when the alleged corrective disclosure was made. The defendants, the company’s officers and directors at all relevant times, their immediate families, legal representatives, heirs, successors and assigns, and any entity in which the defendants have or had a controlling interest are excluded. The class exists only as a proposal until a court certifies it, and its definition can change as the case proceeds.A Separate Shareholder Derivative Suit
On October 13, 2026, another shareholder filed Marti v. Raab, No. 1:26-cv-14635, in the same court. It is a shareholder derivative suit brought on behalf of Ardelyx itself against the four executives named in the class action and seven other directors, covering the same January 13, 2025 to August 6, 2026 period. It asserts claims including breach of fiduciary duty, unjust enrichment, waste of corporate assets and violations of Section 14(a) of the Exchange Act, plus claims for contribution against the four executives. Any recovery in a derivative suit generally goes to the company rather than to individual investors, so it is not a route to compensation for stock losses.What Happens Next
The Private Securities Litigation Reform Act requires the first plaintiff in a securities class action to publish a notice of the case, after which investors have 60 days to ask the court to appoint them lead plaintiff. According to PSLRA notices published by law firms, that deadline in the Ardelyx case is November 16, 2026, which matches the 60-day window from the September 17 filing. The date comes from the notices, not from a court order. After the court picks a lead plaintiff and lead counsel, an amended complaint usually follows, and the defendants typically move to dismiss.The complaint was filed by Levi & Korsinsky, LLP. Members of a proposed securities class generally remain in the class without seeking the lead plaintiff role. There is no money available unless the case produces a settlement or judgment, which would come with its own notice and claim process.
Questions
Who is covered by the Ardelyx securities class action?
The proposed class is everyone who bought or otherwise acquired Ardelyx common stock between January 13, 2025 and August 6, 2026, inclusive, and was damaged when the alleged corrective disclosure was made. The defendants, the company’s officers and directors, their immediate families and entities the defendants control are excluded. No class has been certified.
What is the November 16, 2026 deadline in the Ardelyx case?
According to PSLRA notices published by law firms, November 16, 2026 is the deadline for investors to ask the court to appoint them lead plaintiff under the Private Securities Litigation Reform Act. That matches the statute’s 60-day window from the September 17, 2026 notice. It is not a claim deadline. Members of a proposed securities class generally remain in the class without seeking that role, and there is no money or claim form available.
What does the Ardelyx lawsuit claim was misleading?
The complaint alleges that from January 2025 through April 2026 Ardelyx and four executives expressed confidence in growth and revenue guidance for IBSRELA and XPHOZAH while concealing that increasingly restrictive payer requirements, including prior authorization and step edits, were slowing new IBSRELA patient starts and undermining XPHOZAH’s long-term growth. Ardelyx has not been found liable.
Is the Marti v. Raab case the same as the Ardelyx securities class action?
The two cases are separate. Marti v. Raab, filed October 13, 2026 in the same court, is a shareholder derivative suit brought on behalf of Ardelyx itself against its officers and directors over the same period. Any recovery in a derivative suit generally goes to the company, not to individual investors. The securities class action seeks damages for investors who bought Ardelyx stock during the class period.
Is there an Ardelyx securities settlement to claim?
There is no settlement, fund or claim form. The case is at the complaint stage, no lead plaintiff has been appointed and no class has been certified. Money would become available only if the case produced a settlement or judgment, which would come with its own court-approved notice and claim process.
Sources
- Class action complaint — Broadwater v. Ardelyx, Inc., filed September 17, 2026
- Court docket — No. 1:26-cv-14270 (D. Mass.) (CourtListener)
- Verified shareholder derivative complaint — Marti v. Raab, No. 1:26-cv-14635 (D. Mass.), filed October 13, 2026
- Ardelyx SEC filings — EDGAR company search
